Holen Sie sich die Stockscreener-App
43.46
1.89%
-0.82
Schlusskurs vom Vortag:
$44.28
Offen:
$44.65
24-Stunden-Volumen:
1.06M
Relative Volume:
0.51
Marktkapitalisierung:
$8.18B
Einnahmen:
$550.17M
Nettoeinkommen (Verlust:
$201.35M
KGV:
43.46
EPS:
1
Netto-Cashflow:
$232.07M
1W Leistung:
-0.57%
1M Leistung:
-14.08%
6M Leistung:
-26.76%
1J Leistung:
-18.89%
1-Tages-Spanne:
$43.21
$44.99
1-Wochen-Bereich:
$43.21
$44.99
52-Wochen-Spanne:
$43.21
$85.21
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
43.45 | 8.34B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
220.13 | 36.69B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
61.85 | 10.51B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
91.82 | 7.83B | 1.15B | 96.70M | -161.99M | 1.09 |
|
BTSG
Brightspring Health Services Inc
|
38.34 | 6.75B | 11.99B | 24.18M | 234.31M | 0.2956 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-11-21 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-11-13 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2025-10-27 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-10-01 | Herabstufung | Goldman | Neutral → Sell |
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Fort Washington Investment Advisors Inc. OH Has $16.45 Million Position in Doximity, Inc. $DOCS - MarketBeat
Doximity enters into $31 million settlement agreement to resolve securities litigation - marketscreener.com
DoximityOn December 24, Enters Into $31 Million Settlement Agreement To Resolve Securities Litigation - TradingView — Track All Markets
Doximity Enters Agreement to Settle Securities Litigation for $31 Million - marketscreener.com
Doximity to settle securities litigation lawsuit for $31M - TipRanks
Doximity Reaches Proposed Settlement in Securities Litigation Case - TipRanks
Doximity reaches $31M settlement in securities litigation lawsuit (DOCS:NYSE) - Seeking Alpha
Doximity, Inc. Reaches Settlement in Securities Litigation - TradingView — Track All Markets
Doximity (NYSE: DOCS) agrees to $31M insured settlement in securities case - Stock Titan
Doximity Agrees to $31 Million Deal to End Investor Class Action - Bloomberg Law News
Doximity: Strong Growth but What's Next? - AOL.com
Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More - AOL.com
Why Doximity, Inc. (DOCS) Soared Last Week? - MSN
Raymond James reiterates Strong Buy on Doximity stock, cites physician-first approach By Investing.com - Investing.com Nigeria
Raymond James reiterates Strong Buy on Doximity stock, cites physician-first approach - Investing.com Nigeria
Doximity, Inc. $DOCS Shares Sold by Pacer Advisors Inc. - MarketBeat
Capricorn Fund Managers Ltd Buys New Position in Doximity, Inc. $DOCS - MarketBeat
Doximity Earnings Notes - Trefis
How Doximity Inc stock reacts to global recession fears2025 Earnings Surprises & Reliable Intraday Trade Plans - moha.gov.vn
Rice Hall James & Associates LLC Sells 35,852 Shares of Doximity, Inc. $DOCS - MarketBeat
What Doximity (DOCS)'s PeerCheck AI Review Launch and Analyst Support Means For Shareholders - Sahm
HALPER SADEH LLC ENCOURAGES DOXIMITY INC. SHAREHOLDERS TO CONTAC - GuruFocus
HALPER SADEH LLC ENCOURAGES DOXIMITY INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Doximity (NASDAQ:DOCS) Sets New 1-Year LowHere's Why - MarketBeat
Doximity (DOCS) Stock Falls Amid Market Uptick: What Investors Need to Know - sharewise.com
Doximity stock hits 52-week low at 43.28 USD By Investing.com - Investing.com Nigeria
Doximity stock hits 52-week low at 43.28 USD - Investing.com
Doximity (DOCS) Stock Trades Up, Here Is Why - Finviz
Why Doximity (DOCS) is a Top Growth Stock for the Long-Term - Nasdaq
Riverbridge Partners LLC Has $40.61 Million Stock Holdings in Doximity, Inc. $DOCS - MarketBeat
Why BofA Sees Strong Upside for Doximity (DOCS) - Finviz
BTIG Upgrades Doximity (DOCS) Stock to Buy from Neutral - MSN
Is Doximity Inc. stock attractive for long term wealth buildingJuly 2025 Reactions & Community Driven Trade Alerts - bolumsonucanavari.com
Is Doximity Inc. Class stock considered safe havenJuly 2025 Institutional & Target Return Focused Stock Picks - Улправда
Doximity, Inc. $DOCS Shares Purchased by Voya Investment Management LLC - MarketBeat
Clinical decision support's new chessboard - Axios
Will Doximity Inc. stock outperform tech sector in 2025Forecast Cut & Short-Term High Return Ideas - Улправда
How Doximity Inc. stock compares to industry benchmarksWeekly Market Report & Technical Confirmation Alerts - DonanımHaber
How higher bond yields impact Doximity Inc. Class stockDollar Strength & High Accuracy Trade Alerts - DonanımHaber
How Doximity Inc. stock reacts to global recession fearsWeekly Profit Analysis & Target Return Focused Picks - DonanımHaber
How rising interest rates impact Doximity Inc. stockBond Market & Weekly Breakout Opportunity Watchlist - Улправда
Doximity (NASDAQ:DOCS) Hits New 12-Month LowShould You Sell? - MarketBeat
How Analyst Upgrades Highlighting AI Tools And Ad Shift Potential At Doximity (DOCS) Has Changed Its Investment Story - Yahoo Finance
Is Analyst Upgrades on AI Workflow and Pharma Ads Altering The Investment Case For Doximity (DOCS)? - Sahm
Doximity (DOCS): Assessing Valuation After Analyst Upgrades and Growing AI-Driven Growth Prospects - Sahm
Piper Sandler sees Doximity and Phreesia as oversold, recommends buying By Investing.com - Investing.com South Africa
BofA Securities maintains Buy rating on Doximity stock amid pharma ad trends By Investing.com - Investing.com South Africa
Doximity stock hits 52-week low at 43.59 USD By Investing.com - Investing.com Nigeria
Doximity stock hits 52-week low at 43.59 USD - Investing.com India
Piper Sandler sees Doximity and Phreesia as oversold, recommends buying - Investing.com India
BofA Securities maintains Buy rating on Doximity stock amid pharma ad trends - Investing.com Nigeria
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.36%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):